Priorities include matching engager design to tumor and effector biology, optimizing pharmacokinetic and pharmacodynamic properties, defining predictive biomarkers, and developing rational combinations that translate early responses into durable disease control.
Abstract
Natural killer (NK)-cell engagers (NKCEs) are antibody-based therapeutics that link activating receptors on NK cells to tumor-associated antigens, enabling targeted cytotoxicity. NKCE development has progressed from bispecific CD16A-directed constructs to multispecific platforms incorporating complementary activating receptors, cytokine support, and half-life engineering. These designs offer coordinated control of tumor recognition and NK-cell activation within an off-the-shelf therapeutic format with adjustable dosing and exposure. Early clinical studies demonstrate meaningful antitumor activity and an encouraging safety profile in selected hematologic malignancies, particularly when engagers are combined with preactivated, expanded allogeneic NK cells. Nevertheless, response durability remains variable, and clinical development has been complicated by biological limitations and sponsor-related discontinuations. Solid tumors present additional challenges, including antigen heterogeneity, inadequate NK-cell infiltration, stromal exclusion, and microenvironmental suppression. Soluble NKG2D ligands, particularly sMICA and sMICB, can further impair effector function, supporting investigation of combinations that restore NK-cell competence alongside engager-mediated redirection. This review examines NKCE architectures, mechanisms, clinical progress, and translational challenges. Priorities include matching engager design to tumor and effector biology, optimizing pharmacokinetic and pharmacodynamic properties, defining predictive biomarkers, and developing rational combinations that translate early responses into durable disease control.
Natural killer (NK) cells have emerged as central players in cancer immunotherapy, progressing from basic discovery to clinically validated platforms over five decades. This review synthesizes the evolving understanding of NK cell biology, including subset heterogeneity, epigenetic regulation, and metabolic control, an...
Ai-Qin Zhao, Jing Xu, Wen-Hai Deng et al.· Signal Transduction and Targ...· 0 citations
The structural and mechanistic foundations of TCE activity are examined, including antibody fragment–based constructs, IgG-like bispecific antibodies, T-cell receptor–based engagers, and emerging multispecific platforms, which are positioning TCEs as an increasingly adaptable and durable therapeutic platform for solid...
J. Forero, R. Jani, Xena Zheng et al.· Frontiers in Immunology· 0 citations
Chimeric antigen receptor–natural killer (CAR-NK) cells combine innate cytotoxicity with antigen-directed killing and promise as an immunotherapy with lower cytokine toxicity than CAR-T approaches. However, clinical translation is limited by challenges in transduction, persistence, tumor infiltration, and the immunosup...
S. Awadallah, NourEldin Elmesalamy, A. Bahr et al.· Journal of Cancer Research a...· 0 citations
The natural cytotoxic properties of natural killer (NK) cells together with their suitability for genetic modification have attracted increasing interest in tumour immunotherapy. This review evaluates how NK cell-based therapies have developed, with particular attention to chimeric antigen receptor (CAR)-NK technology,...
Xiao-Mei He· Theoretical and Natural Scie...· 0 citations
Chimeric antigen receptor (CAR)-based immunotherapy has transformed cancer treatment by enabling engineered immune cells to selectively recognize and eliminate malignant targets, with CAR-T cells establishing the first major clinical success in this field. However, severe associated toxicities, logistical complexities...
A. Bahr, Youssef Basem, Amani Alhejely et al.· Frontiers in Genome Editing· 0 citations
Conventional CD8+ T cells can acquire natural killer (NK) cell receptors upon persistent antigen exposure, forming antigen-experienced NK-T (AENK-T) cells. Their dual-state plasticity within the tumor immune microenvironment determines cancer immunotherapy outcomes. This narrative review synthesizes recent transcriptom...